Cargando…

Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome

Glucocorticoid receptor (GR) function may have aetiopathogenic significance in chronic fatigue syndrome (CFS), via its essential role in mediating inflammatory responses as well as in hypothalamic-pituitary-adrenal axis regulation. GR function can be estimated ex vivo by measuring dexamethasone (dex...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynn, Megan, Maclachlan, Laura, Finkelmeyer, Andreas, Clark, James, Locke, James, Todryk, Stephen, Ng, Wan-Fai, Newton, Julia L., Watson, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015684/
https://www.ncbi.nlm.nih.gov/pubmed/29983634
http://dx.doi.org/10.1155/2018/3972104
_version_ 1783334451441303552
author Lynn, Megan
Maclachlan, Laura
Finkelmeyer, Andreas
Clark, James
Locke, James
Todryk, Stephen
Ng, Wan-Fai
Newton, Julia L.
Watson, Stuart
author_facet Lynn, Megan
Maclachlan, Laura
Finkelmeyer, Andreas
Clark, James
Locke, James
Todryk, Stephen
Ng, Wan-Fai
Newton, Julia L.
Watson, Stuart
author_sort Lynn, Megan
collection PubMed
description Glucocorticoid receptor (GR) function may have aetiopathogenic significance in chronic fatigue syndrome (CFS), via its essential role in mediating inflammatory responses as well as in hypothalamic-pituitary-adrenal axis regulation. GR function can be estimated ex vivo by measuring dexamethasone (dex) modulation of cytokine response to lipopolysaccharide (LPS), and in vivo using the impact of dex on cortisol levels. This study aimed to compare the GR function between CFS (n = 48), primary Sjögren's syndrome (a disease group control) (n = 27), and sedentary healthy controls (HCs) (n = 20), and to investigate its relationship with clinical measures. In the GR ex vivo response assay, whole blood was diluted and incubated with LPS (to stimulate cytokine production), with or without 10 or 100 nanomolar concentrations of dex. Cytometric bead array (CBA) and flow cytometry enabled quantification of cytokine levels (TNFα, interleukin- (IL-) 6, and IL-10) in the supernatants. In the in vivo response assay, five plasma samples were taken for determination of total cortisol concentration using ELISA at half-hourly intervals on two consecutive mornings separated by ingestion of 0.5 mg of dex at 11 pm. The association of the data from the in vivo and ex vivo analyses with reported childhood adversity was also examined. CFS patients had reduced LPS-induced IL-6 and TNFα production compared to both control groups and reduced suppression of TNFα by the higher dose of dex compared to HCs. Cortisol levels, before or after dex, did not differ between CFS and HCs. Cortisol levels were more variable in CFS than HCs. In the combined group (CFS plus HC), cortisol concentrations positively and ex vivo GR function (determined by dex-mediated suppression of IL-10) negatively correlated with childhood adversity score. The results do not support the hypothesis that GR dysregulation is aetiopathogenic in CFS and suggest that current and future endocrine cross-sectional studies in CFS may be vulnerable to the confounding influence of childhood trauma which is likely increased by comorbid depression.
format Online
Article
Text
id pubmed-6015684
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-60156842018-07-08 Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome Lynn, Megan Maclachlan, Laura Finkelmeyer, Andreas Clark, James Locke, James Todryk, Stephen Ng, Wan-Fai Newton, Julia L. Watson, Stuart Mediators Inflamm Research Article Glucocorticoid receptor (GR) function may have aetiopathogenic significance in chronic fatigue syndrome (CFS), via its essential role in mediating inflammatory responses as well as in hypothalamic-pituitary-adrenal axis regulation. GR function can be estimated ex vivo by measuring dexamethasone (dex) modulation of cytokine response to lipopolysaccharide (LPS), and in vivo using the impact of dex on cortisol levels. This study aimed to compare the GR function between CFS (n = 48), primary Sjögren's syndrome (a disease group control) (n = 27), and sedentary healthy controls (HCs) (n = 20), and to investigate its relationship with clinical measures. In the GR ex vivo response assay, whole blood was diluted and incubated with LPS (to stimulate cytokine production), with or without 10 or 100 nanomolar concentrations of dex. Cytometric bead array (CBA) and flow cytometry enabled quantification of cytokine levels (TNFα, interleukin- (IL-) 6, and IL-10) in the supernatants. In the in vivo response assay, five plasma samples were taken for determination of total cortisol concentration using ELISA at half-hourly intervals on two consecutive mornings separated by ingestion of 0.5 mg of dex at 11 pm. The association of the data from the in vivo and ex vivo analyses with reported childhood adversity was also examined. CFS patients had reduced LPS-induced IL-6 and TNFα production compared to both control groups and reduced suppression of TNFα by the higher dose of dex compared to HCs. Cortisol levels, before or after dex, did not differ between CFS and HCs. Cortisol levels were more variable in CFS than HCs. In the combined group (CFS plus HC), cortisol concentrations positively and ex vivo GR function (determined by dex-mediated suppression of IL-10) negatively correlated with childhood adversity score. The results do not support the hypothesis that GR dysregulation is aetiopathogenic in CFS and suggest that current and future endocrine cross-sectional studies in CFS may be vulnerable to the confounding influence of childhood trauma which is likely increased by comorbid depression. Hindawi 2018-06-10 /pmc/articles/PMC6015684/ /pubmed/29983634 http://dx.doi.org/10.1155/2018/3972104 Text en Copyright © 2018 Megan Lynn et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lynn, Megan
Maclachlan, Laura
Finkelmeyer, Andreas
Clark, James
Locke, James
Todryk, Stephen
Ng, Wan-Fai
Newton, Julia L.
Watson, Stuart
Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome
title Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome
title_full Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome
title_fullStr Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome
title_full_unstemmed Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome
title_short Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome
title_sort reduction of glucocorticoid receptor function in chronic fatigue syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015684/
https://www.ncbi.nlm.nih.gov/pubmed/29983634
http://dx.doi.org/10.1155/2018/3972104
work_keys_str_mv AT lynnmegan reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome
AT maclachlanlaura reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome
AT finkelmeyerandreas reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome
AT clarkjames reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome
AT lockejames reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome
AT todrykstephen reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome
AT ngwanfai reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome
AT newtonjulial reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome
AT watsonstuart reductionofglucocorticoidreceptorfunctioninchronicfatiguesyndrome